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The prevalence of Clostridium difficile infections has increased due to the emergence of epidemic variants from diverse genetic
lineages. Here we describe the emergence of a novel variant during an outbreak in a Costa Rican hospital that was associated
with severe clinical presentations. This C. difficile variant elicited higher white blood cell counts and caused disease in younger
patients than did other strains isolated during the outbreak. Furthermore, it had a recurrence rate, a 30-day attributable disease
rate, and disease severity as great as those of the epidemic strain NAP1. Pulsed-field gel electrophoresis genotyping indicated that
the outbreak strains belong to a previously undescribed variant, designated NAPCR1. Whole-genome sequencing and ribotyping
indicated that the NAPCR1 variant belongs to C. difficile ribotype 012 and sequence type 54, as does the reference strain 630.
NAPCR1 strains are resistant to fluoroquinolones due to a mutation in gyrA, and they possess an 18-bp deletion in tcdC that is
characteristic of the epidemic, evolutionarily distinct, C. difficile NAP1 variant. NAPCR1 genomes contain 10%more predicted
genes than strain 630, most of which are of hypothetical function and are present on phages and other mobile genetic elements.
The increased virulence of NAPCR1 was confirmed bymortality rates in the hamster model and strong inflammatory responses
induced by bacteria-free supernatants in the murine ligated loopmodel. However, NAPCR1 strains do not synthesize toxin A and
toxin B at levels comparable to those in NAP1 strains. Our results suggest that the pathogenic potential of this emerging C. diffi-
cile variant is due to the acquisition of hypothetical functions associated with laterally acquired DNA.
Clostridium difficile is a Gram-positive, anaerobic, spore-form-ing bacillus recognized as a common source of health care
infections (1). Antibiotic treatment suppresses the intestinal mi-
crobiota, allowing colonization and germination of C. difficile
spores. After colonization, the bacterium produces two exotoxins
that glucosylate monomeric GTPases, i.e., toxin A (TcdA) and
toxin B (TcdB). Their action results in the characteristic pathology
of C. difficile infections (CDIs), ranging from mild diarrhea to
severe pseudomembranous colitis.
Since 2003, highly virulent toxigenic C. difficile strains have
caused epidemics characterized by greater incidence, severity, and
fatality of disease (2). These strains, initially classified as “hyper-
virulent,” cluster into a distinct phylogenetic group (3), being
classified as group BI (restriction endonuclease analysis [REA]),
type NAP1 (pulsed-field gel electrophoresis [PFGE]), ribotype
027 (PCR ribotyping), and toxinotype III (toxin gene polymor-
phism typing) (4). NAP1 strains have spread widely in recent
years. These strains have been responsible for severe epidemic
outbreaks throughout theworld (2, 5, 6) and have been implicated
in the severe outcomes of C. difficile infections (7).
NAP1 strains produce a binary toxin (C. difficile binary toxin
[CDT]) and harbor a point mutation in the tcdC gene, which
encodes a putative negative transcriptional regulator of C. difficile
toxins. It is postulated that the truncated TcdC is unable to down-
regulate tcdA and tcdB transcription, resulting in increased toxin
production (8). Several studies have attributed the hypervirulence
of NAP1 strains to this trait (8, 9). However, other lines of evi-
dence indicate that tcdC truncations and disease severity are not
related (10, 11). Furthermore, the association between increased
in vitro toxin production and strains with high virulence is also
controversial. Akerlund and collaborators (12) noted a correla-
tion between disease severity and toxin concentrations in feces,
but there was no relationship between levels of toxin synthesized
in vitro by a group of NAP1 strains and fecal toxin levels (12).
The prevalence and severity of human infections caused by
strains different from NAP1 are increasing (7, 13–16). For in-
stance, NAP7 (ribotype 078) strains have been associated with
severe disease in younger populations and have been isolated in
cases of community-associated CDIs (17). The clinical spectrum
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induced by these NAP7 strains indicates that theymight represent
an emerging epidemic genotype; however, themolecular determi-
nants associated with this behavior have not been addressed as
thoroughly as for NAP1 strains. Other strains associated with se-
vere disease have been recently described as well (18). In 2009 to
2010, a C. difficile outbreak occurred in a tertiary care hospital in
Costa Rica. In a preliminary study performed with a partial col-
lection of isolates from this outbreak, the presence of the NAP1
genotype was reported (19). Interestingly, a group of fluoroquin-
olone-resistant strains without NAP designation were also iso-
lated (19). In this work, we report a group of C. difficile strains
belonging to a previously undescribed NAP type with pathogenic
potential similar to that of epidemic NAP1 strains. This emerging
genotype is highly resistant to fluoroquinolones and possesses a
deletion in tcdC similar to NAP1 strains; however, it lacks CDT
and does not produce increased amounts of TcdA and TcdB. To-
gether, these results describe the emergence of a C. difficile variant
with high virulence potential.
MATERIALS AND METHODS
C. difficile isolation and strains. Stool samples positive for C. difficile
toxins (Xpect Clostridium difficile toxin A/B test; Oxoid, Basingstoke,
United Kingdom) that were collected during a CDI outbreak were pro-
cessed. Samples were treated with 96% ethanol and inoculated onto ce-
foxitin-cycloserine-fructose agar (CCFA) plates (Oxoid, Basingstoke,
UnitedKingdom),whichwere incubated for 5 days in an anaerobic cham-
ber (Bactron II; Shel Lab,Cornelius,OR) under an atmosphere of 90%N2,
5%H2, and 5%CO2. Colonies were identified phenotypically (RapID 32A
system; bioMérieux, Marcy l’Etoile, France), chemotaxonomically (Sher-
lock fatty acid methyl ester [FAME] analysis system; MIDI, Santa Clara,
CA), and by PCR amplification of the tpi gene (20).
PCR-based genotyping.DNA from each clinical isolate was obtained
from overnight cultures in brain heart infusion (BHI) broth (Oxoid),
using the InstaGene reagent (Bio-Rad, Hercules, CA). Fragments of tcdA,
tcdB, cdtB, and tcdCwere amplified by PCR using primers and conditions
reported previously (21).
Pulsed-field gel electrophoresis. The PFGE procedure used was de-
rived from published protocols (4, 22). Briefly, bacteria from 6- to 8-h
cultures in BHI broth were disrupted in lysis buffer. Agarose plugs were
prepared by mixing equal volumes of bacterial suspensions and Seakem
Gold agarose (Lonza, Basel, Switzerland) in 1 Tris-EDTA (TE) buffer
(Sigma, Deisenhofen, Germany) containing SDS (Sigma). The plugs were
incubated in a buffer composed of lysozyme, RNase A, and mutanolysin
(Sigma). After overnight digestion with SmaI (Roche, Mannheim, Ger-
many), DNA fragments were separated on 1% agarose gels in 0.5 Tris-
borate-EDTA (TBE) buffer (Fermentas, St-Leon-Rot, Germany) contain-
ing 50 M thiourea (Sigma), using a CHEF-DRII system (Bio-Rad).
Images were analyzed with BioNumerics software (version 5.1; Applied
Maths, Austin, TX) and macrorestriction patterns were compared to
those deposited in the database of the National Microbiology Laboratory
of the Public Health Agency of Canada (Winnipeg, Canada).
Antimicrobial susceptibility testing. MICs for ciprofloxacin, moxi-
floxacin, levofloxacin, clindamycin, metronidazole, rifampin, and vanco-
mycin (Sigma) were determined using agar dilution, following the guide-
lines of the Clinical and Laboratory Standards Institute (23). Resistance
breakpoints were set as follows: ciprofloxacin, 4 g/ml; moxifloxacin,
4 g/ml; levofloxacin,4 g/ml; clindamycin,4 g/ml; metronida-
zole,16 g/ml; rifampin,32 g/ml.
Clinical data.The studywas a retrospective cohort studywith patients
with positive and confirmed C. difficile stool cultures. Each case was clas-
sified as nosocomial CDI or community-associated CDI according to cri-
teria from the Infectious Diseases Society of America (IDSA) (24). CDI
severity was categorized by applying the IDSA/Society for Healthcare Ep-
idemiology of America (SHEA) criteria (24, 25) and criteria described by
Zar et al. (26). Clinical data were extracted from patients’ medical records
(27). The 30-day attributable mortality rate was calculated by considering
patients with positive and confirmed C. difficile stool cultures who pre-
sented clinical signs and symptoms of CDI (temperature above 38°C,
white blood cell count above 15,000 cell/mm3, or radiological evidence of
pseudomembranous colitis) and whose death occurred within 30 days
after the first diarrheal discharge. Categorical variables were analyzed by
using logistic regression models, and risk factors were expressed in terms
of odds ratios (ORs) with 95% confidence intervals (CIs). Two-tailed P
values of 0.05 were used for significance. All statistical analyses were per-
formed using IBM SPSS Statistics 20 software (IBM, Armonk, NY). Data
collection was approved by the Ethics Committee of the San Juan de Dios
Hospital (protocol CLOBI-HSJD-018-2009).
Whole-genome sequencing and sequence analysis. Whole-genome
sequences of representative strains of each of the four NAPCR1 subtypes
were obtained usingmultiplexed paired-end libraries and the sequencing-
by-synthesis Illumina HiSeq platform. To this end, reads were assembled
using Velvet (28), and contigs of300 bp were scaffolded with SSPACE
(29) and ordered with ABACAS, using theC. difficile strain 630 genome as
the reference (30). Gaps were filled using GapFiller (31), and the reads
were mapped back to the assembly using SMALT (http://www.sanger.ac
.uk/resources/software/smalt). Single-nucleotide polymorphisms (SNPs)
were identified with RealPhy (version 1.07) (32) or with SAMTools (33).
A dendrogram based on core SNPs was inferred via PhyML (34) and
depicted using FigTree (http://tree.bio.ed.ac.uk/software/figtree). Dele-
tions or truncations in tcdC, as well as mutations in gyrA and gyrB known
to confer fluoroquinolone resistance, were identified using Artemis (35)
and BLAST. Average nucleotide identities (ANIs) were computed using
the genome-to-genome distance calculator at the German Collection of
Microorganisms and Cell Cultures (36), and comparative genomic anal-
yses were performed using the RAST server of the SEED framework (37).
Multilocus sequence typing and ribotyping. The sequence types
(STs) of representative strains for each of the four NAPCR1 PFGE patterns
were determined by using the multilocus sequence typing (MLST) 1.7
servermaintained by the Center for Genomic Epidemiology at theDanish
TechnicalUniversity (38) and the classification schemebased on the genes
adk, atpA, tpi, glyA, dxr, sodA, and recA, as proposed byGriffiths et al. (39).
For ribotyping, primer sequences and reaction conditions were taken
from the report by Bidet et al. (40).
Hamster infection model. For the animal models, one representative
strain was selected from each group isolated during the outbreak. All of
the strains tested were resistant to clindamycin (NAPCR1MIC, 256g/ml;
NAP1 MIC, 16 g/ml; NAP4 MIC, 8 g/ml). Groups of 5 adult female
Syrian Golden hamsters (150 to 180 g) were treated subcutaneously with
10 mg/kg clindamycin phosphate on day 2. On day 0, clindamycin-
treated and nontreated control hamsters were inoculated, through the
orogastric route, with 1,000 spores of the outbreak strains or the nontoxi-
genic ATCC 700057 strain resuspended inDulbecco’smodified Eagleme-
dium (DMEM) (Sigma) (41). Hamsters were monitored at 12-h intervals
for signs of C. difficile infection, such as diarrhea, and death. On days 1, 6,
and 12, fecal pellets and intestinal contents of dead and surviving animals
were processed forC. difficile isolation (42), and the resulting isolates were
typed by PFGE to confirm the identity of the inoculated strain. All animal
experiments were approved by the Animal Care and Use Committee of
the Universidad de Costa Rica (protocols CICUA 01-12 and CICUA
07-13).
Murine ileal loop model. The strains were grown in TYT medium
(3% Bacto tryptose, 2% yeast extract, and 0.1% thioglycolate [pH 6.8])
(Sigma) for the indicated times. Bacteria were removed by centrifugation
at 20,000 g for 30 min, and supernatants were passed through 0.2-m
filters.
Male Swiss mice (20 to 25 g) were fasted overnight and anesthetized
with ketamine (60 mg/kg) and xylazine (5 mg/kg) (König, São Paulo,
Brazil). Through a midline laparotomy, a 4-cm ileal loop was ligated and
injected with 0.3 ml of supernatants or the corresponding control solu-
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tions.Micewere sacrificed 4 h after inoculation, and the length andweight
of the intestinal loops were recorded (43). Intestinal sections were fixed in
formalin and stained with hematoxylin and eosin for histopathological
evaluation. The samples were evaluated for the severity of epithelial dam-
age, edema, and neutrophil infiltration using a histopathological score
(HS) scale ranging from 0 (absence of alterations) to 3 (severe) (44). The
neutrophil accumulation in homogenized ileal tissue was evaluated
through determination of myeloperoxidase (MPO) activity with an assay
using o-dianisidine dihydrochloride (Sigma) and H2O2 (45); the results
were expressed as units ofMPO/100mg of ileal tissue. The concentrations
of the proinflammatory cytokines interleukin 1 (IL-1), IL-6, and tu-
mor necrosis factor alpha (TNF-) in ileal tissue homogenates were de-
termined by commercial enzyme-linked immunosorbent assay (ELISA),
following the instructions of the manufacturer (R&D Systems, Minneap-
olis, MN).
Cytotoxicity assays. Ten-fold dilutions of the supernatants were
added to HeLa cell monolayers grown in DMEM supplemented with 5%
fetal bovine serum. The cells were monitored for the appearance of cyto-
pathic effect (CPE) by optical microscopy. TcdB-specific antiserum
(TechLab, Blacksburg, VA) was used to neutralize the effect of the toxin.
Cytotoxicity was expressed as the inverse of the dilution of the superna-
tants that caused 50% cell rounding in the monolayers (i.e., 50% CPE
[CPE50]).
Toxin quantitation. The toxins were quantified in the same strains as
used for the animal models. The amounts of toxins secreted by the strains
were quantified by Western blotting. Proteins from bacteria-free super-
natants were concentrated by methanol-chloroform precipitation. Pro-
teins were separated in 7.5% SDS-PAGE gels and electrotransferred to
polyvinylidene difluoride (PVDF) membranes. These membranes were
probedwithmonoclonal anti-TcdA (TTC8) or anti-TcdB (2CV) antibod-
ies (tgcBIOMICS, Mainz, Germany) (46). Chemiluminescence signals
emitted after addition of a goat anti-mouse IgG-horseradish peroxidase
conjugate (Invitrogen; Life Technologies, Carlsbad, CA) and the Lumi-
Light Plus Western blotting substrate (Roche) were recorded with a
Chemidoc XRS documentation system (Bio-Rad).
Transcripts of tcdA and tcdB were quantified by quantitative reverse
transcription (qRT)-PCR. The different strains were grown on TYT me-
dium, and 1 109 cells were processed for RNA extraction. Bacteria were
pelleted by centrifugation at 5,000 g and lysedwith lysostaphin (Sigma),
acetic acid, proteinase K (Fermentas; Fisher Scientific, Pittsburgh, PA),
and SDS (Sigma) (47). RNA was isolated with the RNeasy Midi kit (Qia-
gen, Hilden, Germany) and treated with DNase I Turbo (Ambion; Life
Technologies, Austin, TX). Two micrograms of RNA was reverse tran-
scribed to cDNA using RevertAid transcriptase (Fermentas). The ampli-
fication conditions were as reported previously (48). The relative expres-
sion of genes was calculated with the threshold cycle (CT) method,
using the rpoA transcript as an endogenous control.
Nucleotide sequence accession numbers. The sequence information
from this whole-genome shotgun project has been submitted to DDBJ/
EMBL/GenBank under accession numbers JXCP00000000, JXBP00000000,
JXBQ00000000, JXBR00000000, and JXBS00000000, as part of BioProject
PRJNA264745.
RESULTS
Isolation andmolecular characterization of an emerging strain.
During a C. difficile outbreak in a tertiary care hospital in Costa
Rica (Fig. 1), 57 strains were isolated. These strains were assigned
to 16 SmaI macrorestriction patterns using PFGE (Fig. 2A). Of
those patterns, 7 belonged to previously described genotypes
(NAP1, NAP2, NAP4, NAP6, and NAP9), whereas 9 did not
match an existing NAP designation. Four of the unclassified SmaI
PFGE patterns were frequently isolated and were preliminarily
designated NAPCR1 (Fig. 2A). Future allocation of this genotype
into the standard established NAP nomenclature requires the ap-
pearance of additional C. difficile strains displaying related SmaI
macrorestriction patterns in other geographical locations. NAP1
and NAPCR1 strains accounted for the majority of isolates (45%
and 31%, respectively). All of these strains were positive for tcdA,
tcdB, and tcdC. In addition, NAPCR1 strains showed an 18-bp de-
letion in tcdC, as in NAP1 strains, but only NAP1 strains had a
single-base-pair deletion at position 117.
NAPCR1 and NAP1 strains are associated with increased dis-
ease severity. To characterize the clinical and epidemiological
spectra of CDIs produced by the different genotypes, patient data
were classified into three groups, i.e., patients infected with NAP1
strains (n	 26), patients infected with NAPCR1 strains (n	 18),
and patients infectedwith strains of other genotypes (n	 13). The
average ages of patients were significantly different (Table 1);
whereas NAPCR1 strains affected younger patients, NAP1 strains
and strains of other genotypes affected older individuals. Patients
infected with NAPCR1 strains presented higher white blood cell
counts, and most of them were male. In general, there were no
significant differences in the distributions of comorbidities. How-
ever, noticeable numbers of infections with NAP1 and NAPCR1
strains were associated with trauma (Table 2).
CDIs with NAPCR1 (100%) and NAP1 (96%) strains were hos-
pital acquired, whereas 31% of the cases caused by other geno-
types were community-associated CDIs. Patients undergoing
fluoroquinolone therapy were 10 or 14 times more likely to de-
velop infections caused by NAPCR1 or NAP1 strains, respectively,
than infections caused by other genotypes (NAPCR1 versus other
genotypes, P	 0.04 [OR, 9.6]; NAP1 versus other genotypes, P	
0.006 [OR, 14]) (Table 2).
Infections with NAPCR1 and NAP1 strains were more likely to
be associated with increased disease severity, according to the
IDSA/SHEA criteria (NAPCR1 versus other genotypes, P 	 0.03
[OR, 6.87 [95% CI, 1.17 to 40.38]]) and the criteria described by
Zar et al. (26) (NAPCR1 versus other genotypes,P	 0.03 [OR, 5.85
[95%CI, 1.22 to 27.99]]) (Table 2). Recurrencewas 10 and 9 times
more likely in patients infected with NAPCR1 and NAP1 strains,
respectively, than in patients infected with other genotypes
(NAPCR1 versus other genotypes,P	 0.04 [OR, 9.6]; NAP1 versus
other genotypes, P 	 0.03 [OR, 8.8]) (Table 2). Similarly, the
30-day attributable mortality rates for NAPCR1 and NAP1 strains
were significantly higher (17% and 27%, respectively) than that
FIG 1 Epidemic curve for a CDI outbreak at a tertiary care hospital in Costa
Rica, showing the numbers of CDI cases diagnosed (through clinical evidence
and toxin detection) at San Juan deDiosHospital during a 28-month period in
2008 to 2010.
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for strains of other genotypes (P	 0.05 andP	 0.03, respectively)
(Table 2).
Comparative genomic analysis of NAPCR1 strains.To further
study the NAPCR1 variant, we performed whole-genome sequenc-
ing and comparative genomic analysis. All of the NAPCR1 strains
are very closely related, as indicated by the finding of only 101 core
SNPs in the 
4.5-Mb genomes (Fig. 2B). When we compared
NAPCR1 genomes to reference genomes from common C. difficile
FIG 2 Molecular characterization of C. difficile isolates. (A) C. difficile strains (n	 57) isolated during the outbreak were typed by PFGE. Sixteen different SmaI
macrorestriction patterns were detected and classified into the indicated NAP types. A previously undescribed NAP type was highly represented and was
designated NAPCR1. (B) A phylogenomic tree based on core SNPs depicts the high level of genomic similarity of NAPCR1 strains (in bold) and their phylogenetic
relationships to C. difficile 630, two NAP1 strains (R20291 and CD196), a NAP4 strain, and a NAP9 strain (M68). The scale distances correspond to the average
number of substitutions per site.
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strains, the NAPCR1 strains were not related to NAP1 lineages
(68,413 core SNPs). Instead, average nucleotide identity (ANI) of
99%and 405 SNPs distinguished the core genomes ofNAPCR1 and
C. difficile strain 630. By ribotyping we determined that NAPCR1
belongs to ribotype 012, and by MLST we determined that this
strain belongs to ST54 (data not shown). Strain 630 belongs to the
same typing groups, which confirms the close relationship with
NAPCR1.
NAPCR1 strains have more laterally acquired DNA than close
relatives. NAPCR1 has about 6% more DNA and 10% more pre-
dicted proteins than C. difficile strain 630 (4,549,499 bp and 4,201
proteins versus 4,290,252 bp and 3,819 proteins). Compared toC.
difficile strain 630, NAPCR1 has almost twice as many functions
from the category of phages, prophages, transposable elements,
and plasmids (see Table S1 in the supplemental material). Further
functional differences were mostly related to DNA/RNAmetabo-
lism and regulation and cell signaling (see Table S1 in the supple-
mental material). Metabolic reconstruction of the NAPCR1 and C.
difficile strain 630 genomes revealed that theNAPCR1 genotype has
genes from 14 different categories not present in C. difficile strain
630. Six of these categories are associated with phages, and an
additional one has to do with antibiotic resistance. In contrast,
NAPCR1 lacks genes related to chorismate synthesis, Ton and Tol
transport, phage DNA synthesis, and phage-packaging machin-
ery. NAPCR1 and C. difficile strain 630 have 338 and 161 unique
genes, respectively (see Tables S2 and S3 in the supplemental ma-
terial). Almost all unique NAPCR1 sequences encode hypothetical
proteins and cluster in contigs carrying phage genes or, to aminor
extent, antibiotic resistance genes (see Table S2 in the supplemen-
tal material).
NAPCR1 strains display a virulent phenotype.The pathogenic
potential of NAPCR1 strains was compared to that of other geno-
TABLE 1 Characteristics of patients with CDIs caused by different
genotypes
Variablea
NAP1
(n	 26)
NAPCR1
(n	 18)
Other genotypes
(n	 13)
Age (mean SD) (yr) 70 22 48 30b 60 35
Hospital stay before onset of
diarrhea (mean SD)
(days)
11 20 24 47 12 32
a SD, standard deviation.
b P 0.05, compared to each other group, by one-way ANOVA with Bonferroni’s
correction.
TABLE 2 Univariate analysis of risk factors and outcomes of CDIs caused by different genotypes
Parameter
Proportion (%) P (OR [95% CI])a
NAP1
(n	 26)
NAPCR1
(n	 18)
Other
genotypes
(n	 13) NAPCR1 vs NAP1 NAPCR1 vs other genotypes NAP1 vs other genotypes
Male 57.7 88.9 53.8 0.04b (5.86 [1.11-0.95]) 0.04b (6.85 [1.10-42.75]) 1.0 (0.85 [0.22-3.32])
Nosocomial CDI 96.1 100 69.2 1.0 (no ORc) 0.03b (no ORc) 1 (1.11 [1.09-113.06])
Underlying disease
Diabetes mellitus 23.1 16.7 7.7 0.71 (0.66 [0.14-3.11]) 0.38 (3.6 [0.38-33.63]) 0.38 (3.6 [0.38-33.63])
Cardiovascular disease 38.5 16.7 15.4 0.18 (0.32 [0.07-1.39]) 0.66 (1.7 [0.25-11.58]) 0.27 (3.43 [0.62-18.84])
Chronic obstructive
pulmonary disease
11.5 11.1 15.4 1.0 (1 [0.15-6.97]) 1.0 (1.0 [0.13-8.46]) 1.0 (0.71 [0.10-4.93])
Malignancy 30.8 33.3 7.7 1.0 (0.88 [0.24-3.21]) 0.04b (9 [1.0-84.49]) 0.22 (5.33 [0.59-48.30])
Trauma 3.8 27.8 23.1 0.03b (9.61 [1.01-91.15]) 1.0 (1.28 [0.25-6.69]) 0.09 (0.13 [0.12-1.44])
Pharmacotherapy
Antibiotic use within 8 wk
prior to CDI
96.1 94.4 76.9 1.0 (0.68 [0.04-11.63]) 0.28 (5.1 [0.46-55.89]) 0.09 (7.5 [0.69-80.95])
Fluoroquinolone exposure
within 8 wk prior to CDI
53.8 44.4 7.7 0.76 (1.25 [0.38-4.18]) 0.04b (9.6 [1.02-90.34]) 0.006b (14 [1.58-123.95])
Gastric acid suppressors 46.1 55.5 61.5 0.76 (0.68 [0.20-2.30]) 1.0 (0.78 [0.18-3.34]) 0.50 (0.54 [0.14-2.08])
Clinical features
White blood cell count of
15,000 cells/l
38.5 61.1 30.1 0.22 (2.5 [0.73-8.63]) 0.15 (3.54 [0.78-16.03]) 0.73 (1.41 [0.34-5.81])
Albumin level of2.5
mg/dl
61.5 55.5 53.8 0.76 (0.78 [0.23-2.65]) 0.72 (1.45 [0.35-6.11]) 0.73 (1.38 [0.36-5.27])
Fever of38°C 38.5 61.1 69.2 0.22 (2.5 [0.73-8.63]) 0.71 (0.69 [0.15-3.16]) 0.09 (0.28 [0.06-1.14])
Severe disease according to
IDSA/SHEA criteria
50 55.5 15.4 0.76 (1.25 [0.37-4.17]) 0.03b (6.87 [1.17-40.38]) 0.05b (5.50 [1.01-29.85])
Severe disease according to
criteria of Zar et al. (26)
69.2 72.2 30.7 0.55 (1.15 [0.31-4.35]) 0.03b (5.85 [1.22-27.99]) 0.03b (5.06 [1.20-21.42])
Recurrence 30.8 38.9 7.7 0.74 (1.43 [0.40-5.06]) 0.04b (9.6 [1.02-90.34]) 0.03b (8.8 [1.01-78.10])
30-day all-cause death 30.8 16.9 15.4 0.55 (0.32 [0.07-1.39]) 0.84 (1.26 [0.8-4.33]) 0.15 (2.5 [0.77-5.63])
30-day attributable death 26.9 16.9 0 0.49 (0.54 [0.12-2.46]) 0.05b (no ORc) 0.03b (no ORc)
a P values were calculated using Fisher’s exact test.
b Statistically significant (P 0.05).
c OR could not be calculated because one of the proportions was 0% or 100%.
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types isolated in the outbreak by using two animalmodels, i.e., the
hamster-spore infection model and murine ligated ileal loops in-
oculatedwith bacteria-free supernatant. In order to determine the
rates of deaths induced by each genotype, clindamycin-treated
hamsters were infected with spores. NAPCR1, NAP1, NAP4, and
nontoxigenic strains colonized 100% of the hamsters within 6
days. The survival rates of hamsters inoculated with NAPCR1 and
NAP1 spores declined rapidly, with the groups reaching 40% sur-
vival at day 5 and day 3, respectively (Fig. 3). In contrast, the
survival rate for hamsters inoculated with NAP4 spores was 80%
at 12 days after inoculation (Fig. 3). All animals inoculated with
spores from nontoxigenic strains survived the duration of the ex-
periments (Fig. 3). Inoculation of non-antibiotic-treated ham-
sters with spores from all of the genotype groups failed to result in
colonization.
In the ligated ileal loop model, the NAP1 supernatant induced
strong inflammatory reactions, measured as the normalized
weights of the ligated ileal loops (100 15 mg/cm). The NAPCR1
supernatant induced a less severe reaction (66 10 mg/cm) than
that induced by the NAP1 strain; however, the response elicited
was stronger than that induced by the NAP4 supernatant (54 6
mg/cm). Histological analyses indicated that the NAPCR1 and
NAP1 supernatants induced greater inflammatory cell infiltration
and edema than did the NAP4 supernatants (Fig. 4). Only the
NAP1 supernatant induced intense mucosal disruption with epi-
thelial damage (Fig. 4).
We measured the concentration of myeloperoxidase (MPO)
FIG 3 Kaplan-Meier survival curves for hamsters infected with different clin-
ical genotypes of C. difficile. Groups of 5 Syrian Golden hamsters previously
treatedwith clindamycinwere orally inoculatedwith spores from the indicated
genotypes. Hamsters were monitored at 12-h intervals for signs of C. difficile
infection, and the numbers of dead animals were recorded. C. difficile isolates
obtained from fecal pellets were typed by PFGE to confirm the inoculated
strain. , P 0.05 (Mantel-Cox test).
FIG 4 Quantification of histopathological effects of bacteria-free supernatants of the C. difficile genotypes in the murine ligated ileal loop model. Bacteria-free
supernatants (48-h growth) of representative strains from the indicated genotypes were prepared in TYT broth. Six to 8mice per group were inoculated with 0.3
ml of the indicated supernatant in ligated ileal loops. Four hours after inoculation, the mice were sacrificed and the severity of the histopathological alterations
was scored on coded slides, using a histopathological score (HS) scale of 1 (mild) to 3 (severe) for neutrophil infiltration (A), edema (B), and epithelial damage
(C); the general damage induced in the indicated groups was determined as the median of all scores (D). Non-Tox, nontoxigenic. , P 0.05, compared to the
groups without asterisks (Kruskal-Wallis test and Dunn’s multiple-comparison test).
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activity as an indicator of tissue neutrophil infiltration and the
levels of IL-1, IL-6, and TNF- to indicate immune activation at
the ileal tissue level. NAPCR1 and NAP1 supernatants caused sta-
tistically significant increases in MPO activity, in contrast to the
NAP4 supernatant, which elicited a reaction similar to that ob-
served with a nontoxigenic control (see Fig. S1 in the supplemen-
tal material). IL-6 and TNF- levels were strongly induced in ileal
tissue by NAPCR1 and NAP1 supernatants. Again, the NAP4 su-
pernatant induced a reaction similar to that observed with the
nontoxigenic control (see Fig. S1 in the supplemental material).
IL-1 expression was highly induced by the NAP1 supernatant,
compared to the otherC. difficile strains (see Fig. S1 in the supple-
mental material).
NAPCR1 strains are highly resistant to fluoroquinolones.
NAPCR1 and NAP1 strains were resistant to moxifloxacin and
levofloxacin, whereas almost all of the other genotypes were sus-
ceptible to these antibiotics (see Fig. S2 in the supplemental ma-
terial). In addition, the NAPCR1 but not NAP1 strains were also
resistant to clindamycin and rifampin (see Fig. S2 in the supple-
mental material). Since fluoroquinolone resistance in C. difficile
has been attributed to point mutations in either gyrA or gyrB, we
sequenced those genes in selected strains from the outbreak (49).
As reported previously, NAP1 strains presented the Thr82-to-Ile
amino acid substitution in GyrA (50, 51). Among fluoroquin-
olone-susceptible control isolates (NAP4 and NAP6), no muta-
tions were detected in either gyrA or gyrB.
NAPCR1 strains do not produce increased amounts of toxins.
We compared the ability to produce and to secrete toxins in se-
lected strains isolated during the outbreak by measuring toxin
activity, TcdA and TcdB protein levels, and expression of tcdA and
tcdB transcripts. NAP1 strains consistently gave higher cytotoxic
titers than did NAPCR1 and NAP4 strains (Fig. 5A). Supernatants
from each group of strains were collected at different times during
the growth cycle, and the amounts of toxin were determined by
Western blotting. TcdA was detected in NAP1 supernatants
within the first 4 h, and concentrations increased steadily up to 24
h (Fig. 5B). The amounts of TcdA were lower in NAPCR1 and
NAP4 supernatants at all times, being barely detectable at 8 h and
increasing up to 48 h (Fig. 5B). TcdBwas detected inNAP1 super-
natants at 8 h, and its concentration peaked at 24 h. In contrast,
TcdB was detectable in supernatants from NAPCR1 and NAP4
strains only at 24 h, at lower concentrations (Fig. 5B). The tcdA
and tcdBmRNAs were quantified by real-time PCR, and the levels
of both transcripts were higher in NAP1 strains than in NAPCR1
and NAP4 strains at all times tested (Fig. 5C).
DISCUSSION
The incidence and severity of CDIs are increasing throughout the
world (52, 53), a phenomenon that is partly due to the emergence
of epidemic C. difficile strains (13, 14, 18, 54, 55). Here we de-
scribed the emergence of a C. difficile strain with genetic, clinical,
and virulence features that resemble those of NAP1 strains but
within a C. difficile lineage, ribotype 12/ST54, for which no epi-
demic strains have been reported previously.
The NAPCR1 genotype displays a more aggressive phenotype
both in clinically infected patients and in animal models. Patients
whose CDIs were caused by NAPCR1 strains were younger than
those affected by NAP1 and other genotypes and interestingly, as
with the highly virulent NAP1 strains, a significant percentage of
NAPCR1 cases were associated with trauma as a risk factor. These
two epidemiological characteristics depart from the classic profile
for patients affected byC. difficile, which includes age of65 years
and chronic debilitating diseases as risk factors. In addition, pa-
tients affected by NAPCR1 presented recurrence rates and 30-day
attributable mortality rates as high as those presented by patients
affected by NAP1. Furthermore, a majority of patients affected by
NAPCR1 presented white blood cell counts higher than 15,000
cells/l, supporting the proinflammatory nature of the response
elicited by this particular strain (see below). Thus, the clinical
picture induced by NAPCR1 strains, as measured using different
standardized clinical criteria, is as severe as that induced by strains
FIG 5 Quantification of toxin production by the different genotype groups.
(A) Twenty-four-hour bacteria-free supernatants were titrated in 10-fold di-
lutions onHeLa cellmonolayers. Twenty-four hours after inoculationwith the
indicated supernatant, the dilution inducing a cytopathic effect (CPE) for 50%
of the cells was calculated by visual examination under amicroscope. Each bar
represents the CPE50 of one strain. (B) Proteins from bacteria-free superna-
tants obtained at the indicated times were precipitated and separated by 7.5%
SDS-PAGE. Proteins were electrotransferred to PVDFmembranes and probed
with monoclonal antibodies against TcdA and TcdB. (C) Total RNA was pre-
pared from the indicated strains at 5 and 8 h during the growth cycle. RNAwas
retrotranscribed, and cDNA was quantified by real-time PCR using primers
specific for tcdA and tcdB. , P 0.05 (one-way analysis of variance [ANOVA]
with Bonferroni’s correction).
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of the epidemic NAP1 genotype. The NAPCR1 strain was isolated
from approximately one-third of the patients involved in the out-
break described in this report. The epidemic genotype, NAP1, was
detected in a similar percentage, whereas other genotypes were
less frequently represented. It is important to note that in this
study we worked with toxin-positive samples; considering that
NAPCR1 strains do not produce increased amounts of toxins, it is
possible that some milder cases involving this group of strains
were missed and that the overall prevalence of NAPCR1 is even
higher than that reported here.
The more virulent phenotype of NAPCR1 was also demon-
strated with animals challenged orally with spores; the NAPCR1
strain was as virulent as the NAP1 strain in terms of the ability to
decrease the survival rate for clindamycin-treated hamsters. In
contrast, in this model the NAP1 strain has consistently displayed
increased lethality versus strain 630 (41, 56, 57). Considering the
close phylogenetic relationship between NAPCR1 and strain 630
and the fact that both strains are resistant to clindamycin, the
different behavior in the hamster model indicates that the latter
has acquired virulence factors that increase its pathogenicity.
These observations also indicate a positive correlation between
severe CDI outcomes in humans and increased lethality of epi-
demic strains in animal models, thus demonstrating the increased
virulence of NAPCR1.
A factor consistently associatedwith the selection and spread of
NAP1 strains is resistance to fluoroquinolones (6, 49, 50), and it is
well documented that restriction in the usage of these antibiotics
results in decreases of CDIs (58, 59). In this work, we report that
fluoroquinolone resistance is shared by NAPCR1 and NAP1
strains. The NAPCR1 strains harbor the same mutation in gyrA as
reported for fluoroquinolone-resistant NAP1 strains, suggesting
that the two genotypes share the same mechanism of resistance.
This mutation has not been previously reported in ribotype 12/
ST54 (60, 61). This observation reflects the successful nature of
this mutation in conferring fluoroquinolone resistance to C. dif-
ficile in response to the selection pressure imposed by the use of
this family of antibiotics. It is clear that, while fluoroquinolone
resistance is not a molecular determinant of pathogenicity, the
high level of antibiotic resistance introduces a major selection
force that favors the dissemination of epidemic and endemic
strains and thus is a procolonization factor (16).
The pathogenic phenotype ofNAP1 strains has been attributed
to increased production of TcdA and TcdB (9, 62). Some studies
have suggested that this characteristic is related to deletions in the
tcdC gene (8, 63). Thus, we hypothesized that the aggressive phe-
notype demonstrated by the NAPCR1 strain, which also presents
an 18-bp deletion in tcdC, would depend on increased toxin pro-
duction. This was clearly not the case, however, since the levels of
TcdA and TcdB produced by the NAPCR1 strain were significantly
lower than the levels of toxins produced byNAP1 strains. This lack
of correlation between tcdC deletions and increased toxin produc-
tion has been documented previously (11, 64). Despite the pres-
ence of the 18-bp deletion in tcdC, the NAPCR1 genotype does not
exhibit the frameshift mutation at position 117, which probably
has a greater impact on the functionality of TcdC as a negative
regulator of TcdA and TcdB expression (63). Thus, molecular
factors other than increased levels of toxins could account for the
increased virulence observed for the NAPCR1 strain. These factors
could involvemetabolic and/or pathogenic adaptations that allow
the bacteria to colonize the intestines of affected patients more
efficiently. In the murine ligated loop model, we found that the
inflammatory response elicited by NAPCR1 supernatants was al-
most as strong as that induced by NAP1 supernatants, despite the
remarkable differences in TcdA andTcdB concentrations between
the two strains. Thus, we present evidence that the emerging
NAPCR1 genotype is able to induce inflammatory reactions (neu-
trophil recruitment and cytokine induction) and epithelial dam-
age usually attributed to TcdA and TcdB. This capacity may be
associated with other virulence factors that have not yet been de-
scribed for NAPCR1 and that would be responsible for the aggres-
sive pathological response. This hypothesis is in agreement with
recent reports demonstrating several effects of C. difficile on host
immunity that are toxin independent (65–69). Since the NAPCR1
strain belongs to the ribotype 012/ST54 group, for which no epi-
demic strains have been reported previously, its increased viru-
lence could reside in the additional genomic content found in this
genotype, in comparisonwithC. difficile strain 630. It is difficult at
this point to assign the virulent phenotype to a particular set of
genes, due to the large number and hypothetical nature of these
additional open reading frames. However, the abundance and
diversity of prophages found in the emerging NAPCR1 genotype
could play a role in the increased virulence of this strain, since
these genetic elements have been found previously to be in-
volved in the regulation of virulence-associated genes (70–73).
In this scenario, new virulent strains may arise through the
acquisition of foreign DNA, with the ability to modulate im-
mune responses, to tolerate antibiotics, and to regulate expres-
sion of virulence traits.
In conclusion, we described an emerging strain that possesses
increased virulence potential due to the acquisition of laterally
acquired genes and its ability to induce an exacerbated inflamma-
tory response in the gastrointestinal mucosa, through currently
unknown mechanisms. The emergence of strains with increased
virulence is of importance in the surveillance of C. difficile out-
breaks associated with both endemic and epidemic strains.
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